In 2024, Kevin A. Lobo earned $18.94M in total compensation at Stryker, including $1.44M salary, $2.94M bonus and $13.66M in stock. Most recently acquired 133,521 shares in Mar 2025. Currently holds stock worth $65.06M. Has donated $13.59M in stock to charitable causes. Has led Stryker for over 13 years.
Compensation History
Annual executive compensation data for Kevin A. Lobo, including salary, bonuses, and stock awards.
Year
2024
Total Compensation
$18.94M
Salary
$1.44M
Bonus
$2.94M
Other
$897.87K
Salary
$1.44MBoard Justification
We believe that our executive compensation program, which is a key component of our ability to attract, motivate and retain talented, qualified executives, should be designed to provide a meaningful level of total compensation that is aligned with organizational and individual performance and with the interests of our shareholders.
Bonus
$2.94MBoard Justification
Individually structured short-term bonus plans under our Executive Bonus Plan are intended to motivate and reward our NEOs for achieving and exceeding specific annual performance goals. The Compensation and Human Capital Committee approved the 2024 bonus plan target opportunities, bonus plan goals and actual bonus payments for our NEOs other than Mr. Lobo whose 2024 bonus plan target opportunity, bonus plan goals and actual bonus payment were approved by the independent directors of the Board. The primary focus of the 2024 bonus goals for our NEOs was total Stryker performance.
Other Compensation
$897.87KBoard Justification
This includes 401(k) Plan matching contributions and discretionary contributions made in March 2025 pertaining to the 2024 Plan year, in the amount of $35,650 for each NEO and Supplemental Plan matching contributions and discretionary contributions made in March 2025 pertaining to the 2024 Plan year, in the amounts of $538,733 and costs associated with an executive physical examination and the aggregate incremental cost of $321,957 for personal use of aircraft by Mr. Lobo and his family members.
Restricted Stock
Board Justification
Information related to restricted stock units and performance stock units, including dividend equivalents, vested in respect of each of the NEOs during 2024.
Performance Metrics
We used sales, earnings and cash flow goals as the primary measures in the NEO bonus plans for the following reasons: •These are key measures that are the objectives of our strategic plan; •These metrics focus our NEOs on growth, profitability and cash generation/utilization, which are important for our long-term success; •The goals for these metrics generally align with our financial projections; and •We believe these are primary measures our investors monitor in evaluating our performance and making investment decisions regarding Stryker stock.
Kevin A. Lobo
CEO of Stryker
Education
N/A
Field of Expertise
Business & Management
Sector of Economy
Healthcare
Born
August 1, 1965 - 60 years ago
CEO of Stryker for
13 years 2 months (Oct 2012 - Present)
Previous Experience
President of Johnson & Johnson's Ethicon Endo-Surgery subsidiary, held finance positions at KPMG, Unilever Canada, and Kraft Canada.
Other Stryker CEOs
Holdings
Track Kevin A. Lobo's stock holdings and portfolio value over time.
Total Stock Sold
$114.69M
$114.69M
488,016 SYK shares
What if they kept their stock?
If Kevin A. Lobo didn't sell their stock, today they would have:
Extra SYK488,016 shares worth $177.65M.
This is 54.89% and $62.95M more than what they got when they sold the stock.
Charitable Transactions
37,322 shares
SYK
Recent Charitable Transactions
8,904 shares
SYK
Jun 9, 2023
Charity
8,904 shares
SYK
Jun 5, 2023
Charity
19,514 shares
SYK
Mar 21, 2021
Charity
Insider Trading
Kevin A. Lobo's recent stock transactions, purchases, and sales filed with the SEC.
133,521 shares
SYK
Mar 10, 2025
Received
$21.13M
SYK at $368.76/share
Nov 7, 2024
Sale
37,773 shares
SYK
Mar 11, 2024
Received
$16.30M
SYK at $288.67/share
Nov 17, 2023
Sale
8,904 shares
SYK
Jun 9, 2023
Charity
8,904 shares
SYK
Jun 5, 2023
Charity
17,971 shares
SYK
Mar 7, 2023
Received
$16.12M
SYK at $239.79/share
Dec 2, 2022
Sale
$27.57M
SYK at $255.79/share
May 3, 2021
Sale
26,674 shares
SYK
Mar 21, 2021
Received
Rivals
Compare Kevin A. Lobo with competitor CEOs and industry peers.
Javier J. Rodriguez
CEO of DaVita
2022 Compensation
Stock
$0.00
Salary
$1.20M
Bonus
$0.00
Other
$610.78K
Total Holdings
$140.33M
Geoffrey S. Martha
CEO of Medtronic
2023 Compensation
Stock
$0.00
Salary
$1.35M
Bonus
$1.91M
Other
$305.50K
Total Holdings
$89.72K
Steven H. Collis
CEO of Cencora
2023 Compensation
Stock
$0.00
Salary
$1.40M
Bonus
$3.23M
Other
$379.52K
Total Holdings
$242.12M
Gary S. Guthart
CEO of Intuitive Surgical
2022 Compensation
Stock
$5.79M
Salary
$873.08K
Bonus
$1.36M
Other
$1.50K
Total Holdings
$11.23M
Jason M. Hollar
CEO of Cardinal Health
2022 Compensation
Stock
$300.00K
Salary
$1.20M
Bonus
$500.00K
Other
$200.00K
Total Holdings
$728.86K
Michael F. Mahoney
CEO of Boston Scientific
2024 Compensation
Stock
$19.49M
Salary
$1.40M
Bonus
$3.74M
Other
$193.39K
Total Holdings
$42.71M